Granules India Limited · NSE:GRANULES
Granules India — Q3 FY23 Earnings Presentation
15 slides from Granules India's earnings presentation, Jan 24, 2023
Slide 1: Presentation to the Analysts/Investors (exchange cover letter)
G GRANULES REGISTERED OFFICE GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub, Madhapur, Hyderabad - 500 081, Telangana, India. Tel: +91 40 69043500, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com CIN: L24110TG1991PLCO012471 Date: January 24, 2023 To, National Stock Exchan
Slide 2: Granules India Limited Earnings Presentation Q3 FY23
Granules India Limited Earnings Presentation Q3 FY23 1
Slide 3: Safe Harbor
Safe Harbor The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any
Slide 4: Q3FY23: Y-o-Y performance highlights
Q3FY23: Y-o-Y performance highlights Q3 FY23 Q3 FY22 Y-o-Y Gr% Y-o-Y performance Revenue 1,146 997 15% Growth driven by commercialisation efforts made in key geographies including US Value Added 554 465 19% Better VA% due to better product mix Value Added % 48.4% 46.6% EBITDA 231 174 33% EBITDA % 20
Slide 5: Q3FY23: Q-o-Q performance highlights
Q3FY23: Q-o-Q performance highlights Q3 FY23 Q2 FY23 Q-o-Q Gr% Q-o-Q performance Revenue 1,146 1,151 0% Flat Sales on account of 3rd party logistics transition issues in the US which impacted our FD Sales coupled with Price erosion in key geographies including US Value Added 554 572 (3%) This has im
Slide 6: Geographical Mix
Q3FY23 Revenue spilt by Market, Molecules and Segments (In ₹ Mn) Growth in USA due to higher Paracetamol sales Finished Dosage and API segments grew by 14% and 31% respectively Q3FY22 Q3FY23 Geographical Mix 5.3% 6.4% 11,461 Segment Revenue 14.3% 6.7% 9,968 43.1% 5,224 8.4% 10.2% 4,577 FD 49.4% PFI
Slide 7: Last 5 quarters trajectory: Revenue and Profitability
Last 5 quarters trajectory: Revenue and Profitability Revenue from Operations (Rs. Mn.) VA and VA% (Rs. Mn.) EBITDA and EBITDA margins (Rs. Mn.) 11,507 11,461 10,300 5,722 10,196 5,544 9,968 5,060 5,039 2,429 4,648 2,313 2,115 1,927 1,737 49% 50% 50% 48% 47% 17.4% 18.7% 20.7% 17.4%20.2% 21.1% 25.1%
Slide 8: Last 5 quarters trajectory: Key ratios and Cashflow
Last 5 quarters trajectory: Key ratios and Cashflow (In ₹ Mn) Net Debt & Net debt-to-EBITDA (x) Operational Cash Flow Free Cash Flow 1.03 1.00 2,175 1,240 0.98 981 1,807 0.72 1,611 0.61 8,940 49 7,232 6,966 6,132 754 5,538 233 (325) (718) Q3FY22 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q3FY22 Q4FY22 Q1FY23 Q2FY2
Slide 9: ANDA/Dossier filing status
ANDA/Dossier filing status GPI IP GIL IP Filing Status Total USA USA Europe Canada South Africa UK Approved 23 27 4 4 1 59 Tentatively Approved 1 1 2 To be approved 5 11 4 2 3 1 26 Total Products 29 39 8 6 3 2 87 Total GPI products include: ANDA/Dossier filed - Therapeutic area wise CII – 8 PFOS – 4
Slide 10: 5-year trajectory: Revenue and Profitability
5-year trajectory: Revenue and Profitability (In ₹ Mn) Revenue Value Added and VA % 37,649 18,463 18,813 32,375 33,164 16,326 57.0% 13,177 25,986 22,792 10,236 7,955 50.7% 50.0% 16,918 49.2% 47.0% 44.9% FY18 FY19 FY20 FY21 FY22 9M FY23 FY18 FY19 FY20 FY21 FY22 9M FY23 EBITDA & EBITDA Margin PAT & PA
Slide 11: 5-year trajectory: Market and Segment mix
5-year trajectory: Market and Segment mix (In ₹ Mn) Higher revenue contribution coming from Finished Dosage contribution in value going FD segment share increased to 40% to 52% regulated market, 73% of total revenues up in last 5yrs 5% 5% 4% 6% 5% 15% 14% 12% 20% 20% 19,442 39.9% 8% 10% 47.1% 9% 52.
Slide 12: 5-year trajectory: Percentage share from Core and Other Molecules
5-year trajectory: Percentage share from Core and Other Molecules Core Others Para MF IBU GGF MCB Others 14% 17% 15% 16% 14% 15% 16% 14% 14% 15% 19% 17% 18% 19% 17% 16% 3% 16% 1%34% 26% 3% 3% 5% 5% 3% 6% 3% 3% 4% 3% 17% 18% 13% 19% 25% 6% 19% 29% 25% 17% 33% 26% 86% 85% 84% 21% 21% 86% 83% 86% 85% 8
Slide 13: 5-year trajectory: Key Ratios and Cash Flow
5-year trajectory: Key Ratios and Cash Flow (In ₹ Mn) Net Debt & Net debt-to-EBITDA (x) Cash-to-Cash cycle (days) Free Cash Flow (FCF) 9,082 2,919 8,704 135 138 125 3.1 114 117 1,615 6,966 109 6,138 6,058 5,752 2.4 2.1 (172) (647) (1,284) 1.2 1.0 0.7 (4,471) Mar-17 Mar-18 Mar-19 Mar-20 Mar-21 Mar-22
Slide 14: Glossary
Glossary API: Active Pharmaceutical Ingredient PFI: Pharmaceuticals Formulation Intermediates FD: Finished Dosage OTC: Over the counter drugs Rx: Prescription drugs IR: Immediate Release ER: Extended Release CII: Control substances PFOS: Powder for oral suspensions and solutions MUPS: Multi-unit pel
Slide 15: Corporate address
Mr. Puneet Varshney GM Business Finance and Investor Relations Email: puneet.varshney@granulesindia.com www.granulesindia.com Ms. Payal Dave payal.dave@linkintime.co.in Mr. Ashish Chovatia +91 9930044680 ashish.chovatia@linkintime.co.in www.orientcap.com 532482 GRANULES Corporate address: GRAN:IN Fl